Treatment Protocol of the First International Study of Langerhans Cell Histiocytosis in adults

Treatment Protocol of the First International Study of Langerhans Cell Histiocytosis in adults - Treatment of LCH in adults

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30781

Enrollment

Registered

2007-08-08

Start date

2007-09-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Langerhans Cell Histiocytosis

Interventions

Group 1: treatment with Prednisone, Vinblastine and Mercaptopurine. Prednisone is given orally as tablets, daily during the initial 6 weeks, then as 5 daily pulses every 3 weeks during the continuati

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - definitive diagnosis of LCH - no prior cytoreductive treatment for LCH

Exclusion criteria

Exclusion criteria: - patients with severe impairment of clinical condition including severely impaired pulmonary function, long term oxygen therapy or cor pulmonale. - treatment with immune suppressive agents and/or biphosphonates within 4 weeks from baseline evaluation - pregnancy

Design outcomes

Primary

Measure	Time frame
definition and implementation of an uniform treatment for patients with single system LCH, multisystem LCH and pulmonary isolated LCH, implementation of uniform initial evaluation and stratification criteria.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)